CanSino Biologics has agreed with AstraZeneca to provide "contract development and manufacturing services" to support the Anglo-Swedish drugmaker's messenger RNA (mRNA) vaccine programme, the Chinese company said on Tuesday. In a filing to Shanghai's stock exchange, CanSino said it would manufacture and supply unspecified mRNA products to AstraZeneca. AstraZeneca did not have an immediate comment on the announcement.
CanSino Biologics Inc. (OTCMKTS:CASBF – Get Free Report) was the target of a large increase in short interest during the month of July. As of July 15th, there was short interest totalling 1,699,200 shares, an increase of 11.1% from the June 30th total of 1,529,000 shares. Based on an average daily trading volume, of 100 […]
CanSino Biologics Inc. (OTCMKTS:CASBF – Get Free Report) was the recipient of a large increase in short interest in the month of June. As of June 30th, there was short interest totalling 1,529,000 shares, an increase of 12.7% from the June 15th total of 1,357,000 shares. Based on an average trading volume of 4,400 shares, […]
/PRNewswire/ The vaccine research market size is estimated to grow by USD 17.59 billion from 2022 to 2027 at a CAGR of 9.88%, according to Technavio. The.